AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01118403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sultamicillin
Description: Ampoules per 1.5 grams, three grams intravenously every 6 hours for 4 doses diluted in physiologic Sodium Chloride Solution
Study NCT01118403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sultamicillin
Description: Ampoules per 1.5 grams, three grams intravenously every 6 hours for 4 doses diluted in physiologic Sodium Chloride Solution
Study NCT04301934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mona Lisa Touch
Description: Fractional CO2 LASER
Study NCT04301934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conjugated estrogen
Description: Current standard treatment for recurrent UTIs in postmenopausal women
Study NCT04301934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: Current standard treatment for recurrent UTIs in postmenopausal women
Study NCT02596568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: tDCS is a type of brain stimulation that uses low current applied directly over the scalp to increase, or decrease cortical activity under the stimulating electrodes. tDCS applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor. A square wave will be delivered at 0.75 Hz for five blocks of five minutes each with one minute inter-train interval. Stimulation will be applied following 8 epochs of consecutive stage 2 or deeper sleep.
Study NCT02596568 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: tDCS device connected and tested, but not turned on during the night. This has been found to be an effective sham in other studies using this technique.
Study NCT04345900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plinabulin
Description: a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
Study NCT04345900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
Study NCT03641781 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isometric strength training and isokinetic strength training
Description: Isokinetic strength program included strength training at 5 different velocities from slow to fast. Participants were trained on speed of 30°/sec, 90°/sec, 150°/sec, 210°/sec and 270°/sec. Flexion and extension movements were completed with 5 repetitions at each speed.~Participants of isometric strength training group performed isometric contractions at 30°, 45° and 60° of knee flexion with five repetitions at each angle for both hamstring and quadriceps.
Study NCT01141244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT01141244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally
Study NCT03210571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eyeWatch system
Description: The eyeWatch device is composed of an AGDD, a control unit and a draining plate
Study NCT01141244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT01141244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03096743 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MR elastography
Description: MR elastography image acquisition will be conducted on the Compact 3T MRI scanner using a modified single-shot spin-echo echo-planar imaging pulse sequence.
Study NCT03096743 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI structural brain imaging
Description: MRI structural brain imaging will be done on the Compact 3T MRI at the same time as MR elastography.
Study NCT03096743 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Description: All patients with papilledema will get lumbar punctures with opening pressure as part of their work-up for papilledema. A small number of patients without increased intracranial pressure will receive a lumbar puncture.
Study NCT03096743 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT) imaging
Description: Optical Coherence Tomography (OCT) imaging will measure the peripapillary retinal nerve fiber layer (RNFL) thickness measurements The images with enhanced depth imaging will be obtained to measure the Bruch's membrane orientation.
Study NCT00135096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glulisine
Description: PREMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day 0-15 min before the three main meals; metformin (if applicable); and Lantus qd for 52 weeks.
Study NCT00135096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: POSTMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day immediately after a meal (20 min after the start of a meal); metformin (if applicable); and Lantus qd for 52 weeks.
Study NCT02164825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine perineural injection
Description: Ultrasound guided single-shot femoral nerve block
Study NCT02164825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine and ropivacaine
Description: Continuous epidural analgesic perfusion Epidural perfusion with morphine and ropivacaine.
Study NCT02654743 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Children with ASD will receive Sulforaphane in this study
Study NCT04464629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza
Description: Intracanalicular sustained release dexamethasone insert 0.4 mg
Study NCT04464629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate
Description: Topical Prednisolone acetate 1% ophthalmic suspension
Study NCT03909841 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cambridge Neuropsychological Test Automated Battery (CANTAB)
Description: Cognition using Cambridge Neuropsychological Test Automated Battery (CANTAB)
Study NCT03096743 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optic nerve B-scan ultrasound
Description: Ultrasound will be used to measure the optic nerve sheath diameter 3 mm posterior to the posterior scleral surface.
Study NCT03821870 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Inditreat
Description: Tumoroid formation and drug sensitivity analysis
Study NCT03821870 — intervention group
Intervention type: DRUG
Intervention: Experimental drug
Description: Second line treatment based on drug sensitivity analysis
Study NCT03804502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TearCare
Description: The TearCare System warms the eyelids to melt the meibum by applying heat to the external surface of the eyelids for 15 minutes. Following completion of the thermal portion of the procedure, the clinician performs manual expression of each of the eyelids.
Study NCT02322463 — intervention group
Intervention type: DRUG
Intervention: Arab children
Description: Treatment with Oxycodone
Study NCT01737489 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NOOK
Description: will use an electronic reader (Barnes and Noble - NOOK device) to do speech tracking.will do this activity for approximately one hour per day for five days out of seven for a total of four weeks. The speech tracking activity will involve reading approximately two books within the one month time frame. The participants will listen to the book while reading an unabridged book in printed form.
Study NCT01571804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: to receive two identical placebo capsules 1 hr before surgery
Study NCT00944619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed loop
Description: Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
Study NCT00944619 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional insulin pump delivery
Description: Subcutaneous delivery of Novorapid insulin according to usual pump regime
Study NCT04605003 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Novel rig-S
Description: A new device created to hold the high level disinfectant and automatically indicate when sterilisation process has been completed
Study NCT04605003 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Autoclave machine
Description: The gold standard device to clean all medical instruments
Study NCT02763371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary: high GI lunch
Description: High GI: High-GI rice lunch ad libitum on test day 1 and low GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
Study NCT02763371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary: low GI lunch
Description: Low-GI: Low GI-rice lunch ad libitum on test day 1 and high GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
Study NCT01928706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Denture liner Mucopren Soft; Group 1
Description: Complete denture wearers had their existing mandibular dentures relined with a soft silicone-based denture liner (Mucopren Soft; Group 1; n=22)
Study NCT01928706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Denture liner Kooliner; Group 2
Description: Complete denture wearers had their existing mandibular dentures relined with a hard acrylic resin based denture liner (Kooliner; Group 2;n=22) with chairside procedures.
Study NCT01094418 — intervention group
Intervention type: OTHER
Intervention: Nerve conduction studies ( NCS) of the peripheral nerves
Description: Standard NCS of the sural, superficial peroneal sensory nerves, peroneal, tibial motor nerves, radial and median sensory nerves, median motor nerves, F-wave studies of the Tibial and median nerves.~NCS of the distal sensory nerves; dorsal sural Medial dorsal cutaneous and medial plantar nerves.
Study NCT04301908 — intervention group
Intervention type: DRUG
Intervention: interferon
Description: Antiviral therapy for patients with chronic hepatitis B and cirrhosis. Antiviral therapies included interferon and / or nucleoside (acid) analogs, and patients who were continuously treated for more than 6 months were included in the study.
Study NCT03716414 — intervention group
Intervention type: PROCEDURE
Intervention: SLN mapping
Description: Intra-operative SLN mapping with indocyanine green: Intracervical injection will be performed by the surgeon. Sub-mucous injections will be performed with 50% diluted dye at 3 and 9 o'clock positions. 1ml injection contained infracyanine green will be injected deeply into the stroma of the cervix (1cm-depth), and Arms Assigned Interventions another 1ml will be injected superficially (2mm-depth).~The time between the injection and the search for SLN must be as soon as possible.
Study NCT02113189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking program with ankle brace
Description: Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with the bilateral ankle braces on.
Study NCT02113189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized walking program
Description: Walking program will include instructions on walking activities at home such as time of walking
Study NCT02113189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking program with custom braces.
Description: Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with custom-fabricated ankle braces on.
Study NCT02336035 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Volar plate
Description: Flexor carpi radialis (FCR)-approach. Standard surgical procedure with a volar locking plate
Study NCT02730351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/ Vilanterol 100 mcg/25 mcg
Description: FF/VI 100/25 mcg will be administered via ELLIPTA inhaler once daily in the evening
Study NCT02730351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 mcg
Description: FP 250mcg will be administered via DISKUS inhaler, twice daily, once in the morning and once in the evening
Study NCT02730351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo via ELLIPTA inhaler
Description: Placebo will be administered via ELLIPTA inhaler once daily in the evening
Study NCT02730351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo via DISKUS / ACCUHALER
Description: Placebo will be administered via DISKUS / ACCUHALER, twice daily, once in the morning and once in the evening
Study NCT00620555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin
Description: Orally administered gabapentin
Study NCT02789397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab (RTX) and Azathioprine (AZA)
Description: Rituximab 375 mg/m2/dose IV over 4 hours first dose, IV over 2-3 hours each subsequent dose weekly for 4 weeks at enrollment and again at months 6 and 12 for the active comparator arm Rituximab (RTX) and Azathioprine (AZA).
Study NCT02789397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: IV placebo will be administered on the same schedule as Rituximab and oral placebo will be administered by mouth daily for 18 months.
Study NCT04445363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib hydrochloride cream
Description: Jaktinib hydrochloride cream/placebo applied topically in the morning and in the evening, administered continuously for 24 weeks
Study NCT04445363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose extension: Placebo
Study NCT03248531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab in different dosages (dose 1 and 2).
Study NCT03248531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab in different dosages (dose 1, 2 and 3).
Study NCT03248531 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be provided matching Bimekizumab.
Study NCT00815568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate, busulfan
Description: Fludarabine ( 30mg/m2, iv, D-7\~D-2) Busulfan (3.2mg/kg, iv, D-6\~D-3) Total body irradiation (200cGy/day, D-2,-1)
Study NCT00276055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Docetaxel and Bevacizumab
Description: During the treatment phase, pts. will receive the drug combination of gemcitabine, docetaxel, and bevacizumab every 2 weeks for a period of 4 weeks. This 4-week period is called a cycle of treatment. The treatment consists of receiving docetaxel IV over a 60-minute period and gemcitabine IV over a 30-minute period. Pts. will then receive bevacizumab IV over a 30-minute period. Pts. will receive this treatment once every 2 weeks. Pts. will receive at least 2 cycles of treatment unless you have progression of your disease or unmanageable side effects. As long as the size of pts.'s tumor stays the same or gets smaller, pts may continue receiving treatment
Study NCT03240861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-FHBG
Description: Given IV
Study NCT03240861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC
Study NCT03240861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT03240861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellular Therapy
Description: Given LV-NYESO TCR/sr39TK PBSC IV and RV-NYESO TCR PBMC IV
Study NCT03240861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT03240861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT00921427 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vision Restoration Therapy (VRT)
Description: 30 min, twice a day, 3 days a week, 12 weeks
Study NCT00921427 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Vision Restoration Therapy (VRT)
Description: 30 min, twice a day, 3 days a week, 12 weeks
Study NCT03240861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT03240861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis
Study NCT03240861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given SC
Study NCT03240861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT01942824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messages
Study NCT00952861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: 200 mg QD in 5 days
Study NCT00952861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matching)
Description: Placebo QD i 5 days
Study NCT02738541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE
Description: DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
Study NCT02738541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO DENTRIFICE WITHOUT PROPHOSPHATE
Description: PLACEBO DENTRIFICE WITHOUT PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
Study NCT00698438 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ex-PRESS implantation
Description: I. Mobility check of the device. II. Administration of a local or topical anesthetic. III. Preparation and coverage of the eye by conventional sterile procedures. IV. Injection of viscoelastic material into the AC through a paracenthesis. V. Creation of a scleral tunnel up to clear cornea. VI. Creation of a (5 mm) conjunctival tunnel fornix based. VII. Lifting of the conjunctiva and tenon. VIII. Formation of a 2mm scleral incision at 0.3mm depth, 1.5mm from the limbus. IX. Application of 0.5µg/ml MMC under the tunnel for one minute.~X. Penetration into the AC using a 0.65mm stiletto, inside the tunnel of the sclera-corneal junction.~XI. Implantation of the Ex-PRESSTM through that pre-incision at the sclerocorneal junction.~XII. Introducer withdrawal. XIII. Tucking the plate under the scleral tunnel, and verification of the position inside the tunnel.~XIV. Reposition the conjunctiva with 1 - 2 sutures at the limbus. XV. Closing the conjunctiva with a suture.
Study NCT00698438 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Description: standard trabeculectomy
Study NCT04129983 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drugs and Stimulation
Description: 60 cases of sudden deafness were inquired about their medical history and examined by hearing and cranial magnetic resonance. They were randomly divided into two groups and given different treatments. The hearing test was repeated every 7 days. One month and three months after the treatment, the hearing examination was reexamined.
Study NCT03532698 — intervention group
Intervention type: DRUG
Intervention: Aspirin
Description: Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
Study NCT03532698 — intervention group
Intervention type: DRUG
Intervention: Osimertinib
Description: Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
Study NCT03396302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: The self-applied on-line intervention will comprise a three months behavioural intervention composed by 8 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits.
Study NCT03849664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoflavin® solution
Description: Single drip infusion of 20 ml of Cytoflavin® solution in 200 ml of 0.9%NaCl intravenously once a day
Study NCT03849664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoflavin® enteric-coated tablet
Description: 2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
Study NCT03849664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: Single drip infusion of 20 ml of placebo solution in 200 ml of 0.9%NaCl intravenously once a day
Study NCT03849664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo enteric-coated tablet
Description: 2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
Study NCT00394329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone dipropionate
Description: Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) one puff bid